Chlamydia trachomatis persistence in vitro: an overview.
Chlamydiae growing in target mucosal human epithelial cells in vitro can transition from their normal developmental cycle progression, alternating between infectious but metabolically inactive elementary bodies to metabolically active but noninfectious reticulate bodies (RBs) and back to elementary bodies, into a state of persistence. Persistence in vitro is defined as viable but noncultivable chlamydiae involving morphologically enlarged, aberrant, and nondividing RBs. The condition is reversible, yielding infectious elementary bodies after removal of the inducers, including penicillin, interferon-gamma, iron or nutrient starvation, concomitant herpes infection, or maturation of the host cell into its physiologically differentiated state. All aberrant RB phenotypes are not the same, owing to differing up- or down-regulated chlamydial gene sets and subsequent host responses. Although all persistence-inducing conditions exist in vivo, key questions include (1) whether or not aberrant chlamydial RBs occur in vivo during the alternating acute-silent chronic-acute chlamydial infection scenario that exists in infected patients and animals and (2) whether such aberrant RBs can contribute to prolonged, chronic inflammation, fibrosis, and scarring.
Wyrick
Priscilla B
PB
Department of Microbiology, J H Quillen College of Medicine, East Tennessee State University, Johnson City, TN 37614, USA. pbwyrick@mail.etsu.edu
D000900:Anti-Bacterial Agents / Q000494:pharmacology; D002690:Chlamydia Infections / Q000382:microbiology*; D002692:Chlamydia trachomatis / Q000166:cytology / Q000187:drug effects / Q000254:growth & development / Q000472:pathogenicity / Q000502:physiology*; D004717:Endometrium / Q000382:microbiology; D004847:Epithelial Cells / Q000382:microbiology; D005260:Female; D006801:Humans; D010641:Phenotype
D000900:Anti-Bacterial Agents
Microbiol Rev. 1994 Dec;58(4):686-99
7854252
Microb Pathog. 1997 Mar;22(3):133-42
9075216
J Immunol. 1961 Apr;86:382-5
13703027
Infect Immun. 1997 Nov;65(11):4539-47
9353031
Circulation. 2001 Jan 23;103(3):351-6
11157684
FEMS Microbiol Lett. 1993 Jan 15;106(2):193-200
8454184
Am J Reprod Immunol. 2008 Nov;60(5):415-25
18798835
Infect Immun. 1971 Jun;3(6):825-32
16558062
Infect Immun. 1983 Feb;39(2):898-907
6832822
J Bacteriol. 1970 Jan;101(1):278-85
5413965
Am J Pathol. 1993 Apr;142(4):1291-6
8475999
J Immunol. 1986 Jul 15;137(2):689-92
3088106
Am J Obstet Gynecol. 1987 Apr;156(4):824-33
3107388
J Clin Invest. 2003 Jun;111(11):1757-69
12782678
Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8478-83
12815105
Infect Immun. 2003 Aug;71(8):4700-10
12874351
Microb Pathog. 2001 Jun;30(6):337-45
11399140
Infect Agents Dis. 1994 Oct;3(5):218-33
7866655
Proc Natl Acad Sci U S A. 1993 May 1;90(9):3998-4002
8387206
J Antimicrob Chemother. 2004 Jul;54(1):79-85
15163653
FEMS Immunol Med Microbiol. 2008 Oct;54(1):104-13
18657107
Cell Microbiol. 2007 Mar;9(3):725-37
17140408
Infect Immun. 2006 Aug;74(8):4801-8
16861668
Infect Immun. 2007 May;75(5):2374-80
17307941
Cell Microbiol. 2006 Jan;8(1):149-62
16367874
Microb Pathog. 2004 Jan;36(1):35-9
14643638
Infect Immun. 1996 Jun;64(6):1944-9
8675291
JAMA. 1993 Nov 3;270(17):2071-5
8305018
FEMS Microbiol Rev. 2005 Nov;29(5):949-59
16043254
Infect Immun. 2004 Apr;72(4):1843-55
15039303
Infect Immun. 1986 Aug;53(2):347-51
3089936
Br J Vener Dis. 1972 Dec;48(6):437-44
4651178
Mol Microbiol. 2006 Dec;62(5):1387-401
17059564
JAMA. 1967 Nov 6;202(6):467-73
4963708
Proc Soc Exp Biol Med. 1966 Jun;122(2):417-21
5980548
Mol Microbiol. 2001 Aug;41(3):731-41
11532140
Sex Transm Dis. 1985 Jan-Mar;12(1):8-13
4002092
PLoS Pathog. 2007 Jun;3(6):e83
17590080